A Study of Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients with Previously Treated Multiple Myeloma or Plasma Cell Leukemia


About this study

This phase II trial studies how well pomalidomide, ixazomib citrate, and dexamethasone work in treating patients with previously treated multiple myeloma or plasma cell leukemia. Biological therapies, such as pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide, ixazomib citrate, and dexamethasone together may be more effective in treating multiple myeloma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Previously treated myeloma currently with measurable disease
    • Extramedullary disease defined as Plasmacytoma outside bone marrow that is not contiguous with a bone lesion with at least one lesion that has a single diameter of ≥ 2 cm
    • Or Plasma cell leukemia defined as circulating plasma cells exceeding 5% of peripheral blood leukocytes or 0.5 X 10^9/L or 200 cells/150000 events by flow cytometry
  • Calculated creatinine clearance (using Cockcroft-Gault equation) ≥ 30 mL/min
  • Absolute neutrophil count (ANC) ≥ 1000/mm^3
  • Platelet count ≥ 50,000/mm^3
  • Hemoglobin ≥ 8.0 g/dL
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
  • Provide informed written consent
  • Women of childbearing potential, negative pregnancy test done ≤ 7 days prior to registration
  • All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS™) program, and be willing and able to comply with the requirements of the POMALYST REMS™ program
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
  • Willing to provide bone marrow and blood samples for correlative research purposes


Exclusion Criteria

  • Other malignancy requiring active therapy
    • Exceptions: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or carcinoma-in-situ of the cervix
    • Note: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
  • Females of childbearing potential
    • must have a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours prior to prescribing pomalidomide for cycle 1
      • prescriptions must be filled within 7 days as required by RevAssist [lenalidomide REMS program]
    • and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME at least 28 days before she starts taking pomalidomide
    • must also agree to ongoing pregnancy testing
    • men must agree to use a latex condom during sexual contact even if they have had a successful vasectomy
    • patient must follow pregnancy testing requirements as outlined in the POMALYST REMS program
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
  • Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease
  • Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational
    • Note: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
  • Patient has ≥ grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period
  • Major surgery ≤ 14 days before study registration
  • Within 7 days before registration systemic treatment with
    • strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2)
      • fluvoxamine
      • enoxacin
      • ciprofloxacin
    • strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
      • clarithromycin
      • telithromycin
      • itraconazole
      • voriconazole
      • ketoconazole
      • nefazodone
      • posaconazole
    • strong CYP3A4 inducers
      • rifampin
      • rifapentine
      • rifabutin
      • carbamazepine
      • phenytoin
      • phenobarbital
      • Gingko biloba
      • St. John's wort
  • Evidence of current uncontrolled cardiovascular conditions within the past 6 months, including
    • cardiac arrhythmias
    • congestive heart failure
    • angina
    • myocardial infarction 
  • Prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant
  • Corrected QT Interval (QTc) > 470 milliseconds (msec) on a 12-lead ECG obtained during the screening period
    • Note: If a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG
  • Known human immunodeficiency virus (HIV) positive
  • Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
  • Known allergy to any of the study medications, their analogues or excipients in the various formulations
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
  • Diarrhea > grade 1, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading, in the absence of antidiarrheals

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer